Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Beckman Coulter
| Name of analyzer | DxH 690T Hematology Analyzer |
|---|---|
| Company | Beckman Coulter |
| Contact | Eric Pabon |
| City, State | Brea, CA |
| Phone | 714-993-5321 |
| Website | 714-993-5321 http://www.beckmancoulter.com |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × | 40.6 × 29.75 × 32.6 in./9.09 sq. ft. |
| Country where analyzer was | U.S./U.S. |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2020/>530 |
| First year analyzer sold outside | 2020/>410 |
| Foreign locations where company | worldwide (installed worldwide) |
| Human languages (other than | Japanese, Chinese, French, Italian, German, Spanish, Portuguese, Swedish, Greek, Czech, Hungarian, others |
| Analyzer list price | $218, 000 (slide maker stainer sold separately) |
| • Analyzer acquisition options | purchase, lease |
| Training included with purchase/Total time for basic training per operator | 30 min. daily |
| • Follow-up training available | yes (extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, %&# reticulocyte count, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, NRBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis, body fluid analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | CSF, synovial fluid, serous fluid |
| Analytical measurement range for body fluid | RBC count: 1, 000–6, 200, 000 cells/mm3; TNC count: 20–89, 000 cells/mm3 |
| Precision for body fluid | RBC count: 10, 000–15, 000 cells/mm3; TNC count: 50–2, 000 cells/mm3 |
| Accuracy for body fluid | RBC count: 1, 000–6, 200, 000 cells/mm3; TNC count: 20–89, 000 cells/mm3 |
| Automated differential performed for body fluids | no |
| Tests available for research use only | body fluid mononuclear cell %, more |
| Differential methods used | prepared sample transferred to multi-transducer module, with cells counted in an isometric sample stream; algorithm analysis separates WBC into 5 populations |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.050–400.000 × 103 cells/μL/RBC: 0.005–8.500 × 106 cells/μL |
| Precision: • WBC count/RBC count | WBC: 05.00–2.000 × 103 cells/μL: ≤5.0% CV; 5.000–10.000 × 103 cells/μL: ≤3.0% CV/RBC: 4.500–5.500 × 106 cells/μL |
| Accuracy: • WBC count/RBC count | WBC: 0.050–2.000 × 103 cells/μL ±0.1 or ±10%; >2.000–100.000 × 103 cells/μL ±0.2 or ±3.0%; >100.00–400.00 × 103 cells/μL ±5.0%/RBC: 0.005–8.500 × 106 cells/μL |
| Interfering substances: • WBC/RBC | NRBCs, giant platelets, platelet clumps, malarial parasites, precipitated elevated proteins, more/very high WBC count, high concentration of very large platelets, autoagglutination |
| • Hemoglobin/Platelets | severe lipemia, heparin, certain unusual RBC abnormalities that resist lysing/giant platelets, platelet clumps, WBC and RBC fragments, electronic noise, very small RBCs |
| • Hematocrit/Reticulocytes | very high WBC count, high concentration of very large platelets, more/erythrocyte inclusions stained by new methylene blue if sufficiently numerous within sample, more |
| • Automated differential | hypogranular granulocytes, agranular granulocytes, lyse-resistant RBCs, elevated triglycerides, more |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 100/100 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | none |
| Min. specimen volume open mode/Closed mode/Microsample capability | 165 μL/165 μL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | results, including graphics, raw data files/100, 000 |
| Analyzer performs delta checks | yes |
| Parameters for which flags may appear | delta checks, reference range flags, action limit flags, critical limit flags, suspect messages, more |
| Analyzer recognizes and holds test results | yes, for follow-up, confirmatory testing, and potential test rerun (parameters for flags to hold samples defined by client or vendor) |
| Scattergram display uses cell-specific color | yes |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | proprietary (analyzer or vendor specific), ASTM 1394-91, ASTM 1238-95, IEEE MIB |
| • Middleware interface | yes (can use company’s middleware) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, histograms, scatterplots, patient demographics, patient orders, more |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes (also provides list of machine codes for each test and corresponding LOINC code) |
| Lab automation system or workcells to which analyzer has a direct interface | Beckman Coulter |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128, Interleaved 2 of 5, NW-7, ASTM |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes |
| No. of onboard reagents required for standard specimen analysis | 4 |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/variable |
| Notes | — |